This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma or Untreated Childhood Rhabdomyosarcoma
and you are
under 49
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving temozolomide and cixutumumab together with combination chemotherapy may kill more tumor cells.

Provided treatments

  • Biological: Cixutumumab
  • Drug: Cyclophosphamide
  • Biological: Dactinomycin
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Drug: Ifosfamide
  • Drug: Irinotecan Hydrochloride
  • Other: Laboratory Biomarker Analysis
  • Drug: Temozolomide
  • Drug: Vincristine Sulfate Liposome

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01055314. The sponsor of the trial is National Cancer Institute (NCI) and it is looking for 175 volunteers for the current phase.
Official trial title:
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma